CN107404876B - 抗癌治疗剂 - Google Patents

抗癌治疗剂 Download PDF

Info

Publication number
CN107404876B
CN107404876B CN201680018509.6A CN201680018509A CN107404876B CN 107404876 B CN107404876 B CN 107404876B CN 201680018509 A CN201680018509 A CN 201680018509A CN 107404876 B CN107404876 B CN 107404876B
Authority
CN
China
Prior art keywords
cancer
aoh39
compounds
cell
capcna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680018509.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107404876A (zh
Inventor
罗伯特·J·基希
琳达·H·马尔卡斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RLL LLC
Original Assignee
RLL LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RLL LLC filed Critical RLL LLC
Publication of CN107404876A publication Critical patent/CN107404876A/zh
Application granted granted Critical
Publication of CN107404876B publication Critical patent/CN107404876B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680018509.6A 2015-04-10 2016-04-08 抗癌治疗剂 Active CN107404876B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/684,259 2015-04-10
US14/684,259 US10420840B2 (en) 2015-04-10 2015-04-10 Anticancer therapeutic agents
PCT/US2016/026619 WO2016164707A1 (en) 2015-04-10 2016-04-08 Anticancer therapeutic agents

Publications (2)

Publication Number Publication Date
CN107404876A CN107404876A (zh) 2017-11-28
CN107404876B true CN107404876B (zh) 2023-04-14

Family

ID=57072079

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680018509.6A Active CN107404876B (zh) 2015-04-10 2016-04-08 抗癌治疗剂

Country Status (12)

Country Link
US (1) US10420840B2 (enExample)
EP (2) EP3280261B1 (enExample)
JP (1) JP6748704B2 (enExample)
CN (1) CN107404876B (enExample)
AU (1) AU2016245886B2 (enExample)
BR (1) BR122023024844A2 (enExample)
CA (1) CA2978965C (enExample)
ES (1) ES2991018T3 (enExample)
FI (1) FI3878444T3 (enExample)
PL (2) PL3280261T3 (enExample)
PT (1) PT3878444T (enExample)
WO (1) WO2016164707A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119013247A (zh) * 2022-03-07 2024-11-22 希望之城 Pcna抑制剂及其用途
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
EP1874823B1 (en) 2005-04-27 2016-01-13 Indiana University Research and Technology Corporation Cancer specific pcna isoform binding antibodies and uses thereof
CA2612695A1 (en) * 2005-06-27 2007-01-04 Derek J. Hoelz Cspcna isoform modifications and uses thereof
CN101384618A (zh) * 2006-02-17 2009-03-11 印第安纳大学研究及科技有限公司 癌中capcna蛋白-蛋白相互作用的肽基抑制
US20090123487A1 (en) 2007-09-19 2009-05-14 Katia Rothhaar Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CA2732737C (en) * 2008-07-24 2019-03-05 Indiana University Research And Technology Corporation Cancer peptide therapeutics
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
US10550070B2 (en) * 2015-09-17 2020-02-04 City Of Hope PCNA inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Target validation and structure-activity analysis of a series of novel PCNA inhibitors;DILLEHAL K L ET AL;《PHARMACOLOGY RESEARCH AND PERSPECTIVESW》;20150301;第3卷(第2期);e00115 *

Also Published As

Publication number Publication date
AU2016245886A1 (en) 2017-10-12
EP3280261A1 (en) 2018-02-14
FI3878444T3 (fi) 2024-11-19
JP2018510917A (ja) 2018-04-19
EP3280261A4 (en) 2018-12-12
AU2016245886B2 (en) 2020-04-30
CN107404876A (zh) 2017-11-28
US20160296482A1 (en) 2016-10-13
PT3878444T (pt) 2024-11-08
US10420840B2 (en) 2019-09-24
PL3878444T3 (pl) 2025-01-07
CA2978965A1 (en) 2016-10-13
EP3878444A1 (en) 2021-09-15
BR112017019983A2 (pt) 2018-06-19
PL3280261T3 (pl) 2021-09-06
CA2978965C (en) 2023-11-14
EP3878444B1 (en) 2024-10-09
WO2016164707A1 (en) 2016-10-13
EP3280261B1 (en) 2020-12-23
BR122023024844A2 (pt) 2024-01-23
ES2991018T3 (es) 2024-12-02
JP6748704B2 (ja) 2020-09-02

Similar Documents

Publication Publication Date Title
US20170259081A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
RU2764116C2 (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
JP6570512B2 (ja) 新規なＳｔａｔ３阻害剤
CA2730428A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
EP2825173B1 (en) Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
CN107404876B (zh) 抗癌治疗剂
JP7353663B2 (ja) Ｇａｂａａ受容体リガンド
US20130345231A1 (en) Anticancer therapeutic agents
WO2013138600A1 (en) Radioprotector compounds
US11357766B2 (en) Compositions and methods for treating cancer
EP3908575A1 (en) Alk5 inhibitors for treating myelodysplastic syndrome
HK40058784A (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK1246085B (en) Anticancer therapeutic agents
BR112017019983B1 (pt) Agentes terapêuticos anticâncer
US20220339145A1 (en) Compositions and Methods for Treating Cancer
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
WO2023175615A1 (en) Arts mimetic componds and combinations thereof for treating high-risk neuroblastoma
EA049291B1 (ru) Способы лечения рака предстательной железы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant